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We incorporate a new section in Redox Biology, the Editors'
forum. The main objective is to attract short contributions related
to previously published articles that may help to clarify concepts,
open controversies or constructively criticize conclusions from a
speciﬁc article. The contribution will show a link to the related
article and may be accompanied by the appropriate response of
the authors to the commentary on their article.
The article by Drs. Cortese-Krott and Kelm [1] promoted an
extensive analysis by Dr. Tsikas about the optimal methodology to
characterize eNOS activity in red blood cells and its relevance for
the concepts put forward by Cortese-Krott and Kelm. The authors
were given the opportunity to respond to this commentary and
their answer is shown below the commentary. Indeed this is an
important question as the jury appears to be still out concerning
the existence of a NOS isoform in human red blood cells. Dr. Tsikas
makes a strong case on the validity of the gas chromatography-
mass spectrometry (GC-MS) NOS activity assay for a large set of
samples, including erythrocytes, and delves into the complex
chemistry involved. Drs. Cortese-Krott and Kelm lucidly respond
to Dr.Tsikas with equally powerful arguments. We are proud to
host this illuminating discussion on a complex chemical topic and
we invite all readers to follow this example and submit commen-
taries that may contribute to enhance progress in the under-
standing of challenging notions in the ﬁeld of redox biology.
http://dx.doi.org/10.1016/j.redox.2015.01.018
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To the Editor
I read with interest the article by Cortese-Krott and Kelm [1] who
reviewed and discussed the at ﬁrst glance paradoxical, yet potentially
important and formidably challenging issue of nitric oxide (NO)
synthesis from L-arginine by endothelial NO synthase (eNOS) in red
blood cells (RBCs), a possibly new erythrocrine function. In considera-
tion of the high concentration of hemoglobin in erythrocytes (about
10 mM) and the high afﬁnity of O2, NO and carbonmonoxide (CO) and
presumably of other gases to the heme group of hemoglobin, the
majority of scientists believes that RBCs behave toward NO as do
super-massive black holes behave against matter and even light, with
other words as “NO sinks”. Yet, in practice we see that RBCs are able to
export NO and other NO species that can ﬁnally exert cGMP-
dependent and cGMP-independent NO-related activities in the circu-
lation. With respect to this issue I fully agree with the statements,
arguments and conclusions by Cortese-Krott and Kelm in their review
article [1]. However, I do not agree with the authors on their argument
concerning the alleged chemistry of NOS-derived NO in RBCs and that
this particular NO chemistry may explain our failure to measure NOS
activity in human RBCs by means of a previously reported, fully-
validated [2] and cross-validated [3] gas chromatography-mass spec-
trometry (GC–MS) NOS activity assay.
The principle of our GC–MS NOS activity assay [2] used in vivo and
in vitro in blood cells including human RBCs [4] and platelets [3,5] and
the major reactions of NO and its major metabolites/reaction products,
nitrate and nitrite, are illustrated in Fig. 1. We use L-[guanidino-15N2]-
arginine as the substrate for NOS which oxidizes one of the two 15N-
labelled atoms of L-[guanidino-15N2]-arginine to 15NO, with L-[urei-
do-15N]-citrulline being the second reaction product. Because authen-
tic 15NO is not detectable at low NOS activity values as in the case of
endothelial NOS (eNOS), analytically accessible metabolites/reaction
products of 15NO are analyzed instead. It must be emphasized that all
eNOS activity assays are exclusively based on the measurement of NO
metabolites/reaction products because of the pretty low NO formation
rate. In aqueous solutions including blood 15NO is autoxidized to 15N-
nitrite (15NO2—), albeit to a minor extent [6]. NOS isozymes are able to
oxidize its own 15NO to 15N-nitrate (O15NO2—) [3]. In aqueous solutions
of recombinant eNOS solutions and in washed human platelets sus-
pensions, the 15NO2—-to-O15NO2— molar ratio is about 1:1 [5]. In human
erythrocytes suspensions in regular buffers of neutral pH value or in
whole blood [6], 15NO-derived 15NO2— is practically undetectable,
because 15NO is rapidly oxidized by oxyhemoglobin (HbFeIIO2) to
O15NO2—. Thus, in RBCs eNOS would convert L-[guanidino-15N2]-argi-
nine to 15NO which would be oxidized to O15NO2— largely by HbFeIIO2
and to a minor extent by eNOS (Fig. 1). In theory, a very small fraction
of L-[guanidino-15N2]-arginine/eNOS-derived 15NO would autoxidize to
15NO2— which would almost uniformly partition between plasma and
RBCs. Erythrocytic 15NO2— would ﬁnally be oxidized to O15NO2— by
HbFeIIO2. This is supported by our observation that synthetic 15NO gas
is oxidized in humanwhole blood to O15NO2— and 15NO2— with a molar
ratio of about 250:1 after 15 min of continuous 15NO bubbling at
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25 °C [6]. As rightly discussed by Cortese-Krott and Kelm [1], NO in
general and 15NO in case of using L-[guanidino-15N2]-arginine as well
as unlabeled nitrite (i.e.,14NO2—) and 15NO2—would undergo additional,
yet less abundant reactions with hemoglobin species and presumably
with other erythrocytic biomolecules including enzymes such as
xanthine-oxidoreductase (XOR) and carbonic anhydrase (CA) (Fig. 1).
Because nitrate is by far the most abundant NO metabolite in human
RBCs [6–8], there is no doubt that measurement of O15NO2— in lyzed
RBCs will ultimately reﬂect NOS activity. As soon as 15NO is formed
from eNOS-catalyzed oxidation of L-[guanidino-15N2]-arginine exter-
nally added to RBCs, the subsequent reactions will not compromise at
all the assessment of eNOS activity by measuring O15NO2— by our GC–
MS method. Under the conditions we used to measure NOS activity in
RBCs, we measured a half-life of about 12 min for 15NO2—, which,
moreover, is almost entirely oxidized to O15NO2— [6]. To the best of my
knowledge, there is no single published study to report on complete
reduction of nitrate, nitrite of S-nitrosothiols to NO in RBCs, for
instance by XOR, CA, methemoglobin or ceruloplasmin, at least in
freshly obtained and used human RBCs. Therefore, the statement by
Cortese-Krott and Kelm [1] “Measuring changes in 15N/14N-nitrite or
15N/14N-nitrate ratios after incubation with 15N L-arginine [71] in the
presence of high concentrations of hemoglobin may not necessarily
reﬂect true NOS activity because the chemistry of formation of nitrite
and nitrate from NO may be dependent on other competing reactions
involving NO/NO metabolites and oxy/deoxy/methemoglobin (metHb,
FeIIIHb) occurring, which could conceivably affect not only NO but also
nitrite and nitrate levels. These considerations include, but are not
limited to the oxyHb-dependent conversions of NO and nitrite to
nitrate [42], the presence of ceruloplasmin [73] and/or other plasma
proteins converting NO into nitrite, and the enzymatic conversion of
nitrite back to NO (for example catalyzed by XOR [43])” is not
supported by any experimental data. In this context, we should also
not disregard the several orders of magnitude molar excess of hemo-
globin over diaminoﬂuorescein (DAF) reagents. With respect to our
fully-validated GC–MS NOS activity assay [2], which is both speciﬁc
and sensitive and works equally well in numerous complex biological
matrixes, including plasma, serum, whole blood, erythrocytes, saliva,
urine, tissues (liver, kidney, stomach, lung, brain), and various cells [2–
6,9–11], the failure to measure NOS activity in RBCs [4] and platelets
[5] of healthy subjects under regular experimental conditions is not an
analytical issue. With regard both to human RBCs and human
platelets, our studies indicate that these cell types lack NOS activity.
As to human blood platelets, there is convincing evidence by a
proteomics-based study that these cells do not express any NOS
proteins [12]. Detection of NOS proteins in human blood platelets
by many other groups are likely to be due to the use of unspeciﬁc
NOS antibodies [13]. It is generally accepted for many years that
(human) blood platelets express functional NOS. However, not
only recently reported studies but also studies reported 25 years
ago, for instance by the group of Vane [14], suggest that human
platelets lack NOS activity and that measurement of NOS activity
in platelets preparations are likely to be artefactual due to
contaminating neutrophils and mononuclear cells [14].
Kelm and his scientiﬁc partners are long-standing leaders in
the area of NO research and have contributed signiﬁcant work
including the development of sophisticated analytical methods
and clinical protocols to study the pathophysiology of NO in
the human vasculature. Kelm and colleagues reported both on
the expression and the functionality of eNOS in RBCs of healthy
and sick subjects [15,16]. As our group did not investigate the
occurrence of NOS proteins in human RBCs, we cannot com-
ment on the presence or absence of NOS proteins in human
RBCs (and human blood platelets). Yet, the discrepancy con-
cerning the functionality of NOS in human RBCs between our
groups remains unresolved at present. Even if NOS would be
present and active in RBCs, its activity would be very low. I am
convinced that the most reliable way to assess NOS activity is
the use of L-[guanidino-15N2]-arginine and the measurement of
analytically easily accessible 15NO metabolites, i.e., O15NO2—
(and perhaps 15NO2—) in RBCs. Measurement of unlabeled nitrite
(i.e., 14NO2—) and/or nitrate (i.e., O14NO2—) always bears the risk
of detecting nitrite and/or nitrate not deriving from the
L-arginine/NOS system in RBCs during the performance of the
NOS assay. Besides XOR, CA isozymes, which are abundantly
present in RBCs, may also artefactually contribute to NO
unrelated to the L-arginine/NOS pathway [17—19]. Measure-
ment of unlabeled, stable-isotope labeled [3] and/or radio-
labeled citrulline produced from the respective L-arginine
species by enzymes-involving pathways distinctly different
from L-arginine/NOS also bears the risk of detecting artefac-
tually NOS activity.
Speciﬁc detection of NOS proteins and unequivocal measurement
of their activity in blood cells are big analytical challenges. Our
knowledge about NO chemistry, biochemistry and pathophysiology
grew enormously in the past decades. The unimaginable complexity of
the cellular biology bears a high risk of generating inaccurate analytical
results and of drawing uncertain conclusions. By nature, RBCs repre-
sent an especially difﬁcult terrain to NO researchers interested in
expression and functionality of erythrocytic NOS, like the black holes
to astronomers. The enigma and the paradox of expression and
Fig. 1. Schematic of the GC–MS-based NOS activity assay [2] adopted for the measurement of NOS activity in RBCs [4]. The externally added substrate L-[guanidino-15N2]-
arginine is transported inside the RBCs. Functional NOS would convert L-[guanidino-15N2]-arginine to L-[ureido-15N]-citrulline and 15NO. A small portion of 15NO would
autoxidize to 15N-nitrite (15NO2—) and in part be oxidized to 15N-nitrate (O15NO2—) by NOS itself. The major fraction of 15NO would be oxidized to O15NO2— by oxyhemoglobin.
15NO-derived 15NO2— would also be oxidized to O15NO2— by oxyhemoglobin. In addition to these reactions, 15NO and 15NO-derived 15NO2— may undergo further, yet much less
abundant reactions. However, the ﬁnal and most abundant L-[guanidino-15N2]-arginine/15NO-derived metabolite would be O15NO2—. 15NO2— and O15NO2— are simultaneously
derivatized with pentaﬂuorobenzyl bromide and then simultaneously analyzed by GC–MS (not shown); the detected ions are 15NO2— and O15NO2— [2, 4]. Hb, hemoglobin;
XOR, xanthine-oxidoreductase; CA, carbonic anhydrase. The width of the arrows is only an approximate indicator of the contribution of the respective reactions.
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functionality of NOS in RBCs remain to be elucidated. Mass spectro-
metry is the key analytical tool in this endeavor.
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Response to commentary
Miriam M. Cortese-Krott, Malte Kelm
In our article [1] we discussed the history of detection,
unequivocal identiﬁcation by enzymatic and analytical techniques
including electrospray ionization tandem mass spectrometry (ESI-
MS/MS), and potential pathophysiological signiﬁcance of red cell
eNOS, i.e. nitric oxide synthase isoform 3, or "endothelial" isoform
carried by red blood cells (RBCs), and put forward the hypothesis
that red cell eNOS may play a role in the signaling and function of
RBCs and possibly cardiovascular pathophysiology.
As pointed out by Dr. Tsikas in his current letter to the Editor of
Redox Biology, his group never investigated the occurrence of
NOS/eNOS protein in RBC; rather, he reported on the capacity of
RBC suspensions or lysates to convert L-15N-arginine into 15N-
nitrate. These results were published in a Letter to Blood in May
2012 [2], which to the best of our knowledge is the only publica-
tion to date that presented data related to the enzymatic conver-
sion of L-15N-arginine to 15N-nitrate in RBC. Those results show
that (A) suspensions of RBC (from 1 blood donor) take up 15N
arginine in the presence and absence of glucose (Fig. 1A); B) the
ratios of 15N/14N-nitrite and 15N/14N-nitrate, in an RBC suspension
(from 1 blood donor), do not differ at all (nitrite) or increase only
marginally (nitrate) when cells were incubated with 0.4 mM
L-15N-arg at 37°C for 20 min (Fig. 1B); C) addition of 5 mM
L-15N-arg to RBC lysates (from EDTA blood of 5 donors) - the ratio
of 15N/14N nitrate did not change with time (Fig. 1C) whereas the
ratio changed from 0.008 to 0.012 after addition of 50 µg/ml
recombinant human eNOS (Fig. 1C).
Thus, these results seem to demonstrate that addition of 15N-L-
arginine does not affect the 15N/14N-nitrate ratio, and that even the
addition of excess recombinant eNOS increases these ratios only
by 1.5 fold, failing to increase further with time. Considering that
the commercial recombinant eNOS enzyme preparation used has
an activity of at least 125 U/mg (http://www.enzolifesciences.com/
ALX-201-853/enos-human-recombinant/), and that the amount of
enzyme added was 50 µg/ml, this should have resulted in a speciﬁc
activity of at least 6.25 nmoles NO/ml/min or an NO yield of 187.5
nmoles/ml (i.e. µM) over a 30 min incubation period. It is surpris-
ing that the addition of such signiﬁcant amounts of recombinant
eNOS to RBC lysates increased the 15N/14N-nitrate ratio only
1.5 fold, and failed to increase this ratio beyond 20 min of
incubation. Thus, either NOS cofactors were severely limited
and/or the method of detection of the NOS products was not very
sensitive in this matrix. Now considering that in our and other
investigators' hands both the amount of protein, and its activity is
low (e.g. [1,3–9], it would not be expected that the method
proposed by Dr. Tsikas was indeed able to detect differences in
ratios between 15N/14N-nitrate in RBC lysates or in the supernatant
of these cells. In previous work by ourselves and other labora-
tories, the activity of the enzyme was assessed by analyzing the
NOS-dependent conversion of L-3H-arginine, 14C-arginine or 15N-
arginine to the corresponding L-citrulline and by functional assays.
The speciﬁcity of the measurements was controlled (1) by using
NOS inhibitors [6,9]}; (2) by omitting Ca++/CaM in the reaction
buffer [6] or adding EDTA [4] or (3) by using RBC frommice lacking
eNOS [7,10] - all controls needed for validating any technique
aiming at investigating NOS activity.
Regarding the criticism about the "alleged chemistry" of the
NO/nitrite and nitrate equilibria in human RBCs (without con-
sidering of course S-nitrosothiols [11]), we invite Dr. Tsikas to
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